Objective: The present study was performed to elucidate the possible role of SIRT1 signaling in joint inflammation in human articular chondrocytes. Design: Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting were performed to detect gene products and proteins involved in tumor necrosis factor a (TNF-a)-induced inflammation and cartilage degradation in human primary chondrocytes. Matrix metalloproteinase (MMP)-2 and MMP-9 activity was evaluated by gelatin zymography. Overexpression and knockdown of SIRT1 were also performed to investigate whether SIRT1 is associated with the antiinflammatory activity of resveratrol in chondrocytes. Results: Resveratrol dose-dependently inhibited TNF-a-induced cyclooxygenase-2 (COX-2), MMP-1, MMP-3, MMP-13 and PGE 2 production in human chondrocytes. Moreover, MMP-2 and MMP-9 activity was increased by treatment with TNF-a; however, SIRT1 activation decreased the proinflammatory effects induced by TNF-a. In addition, treatment of SIRT1 activator and overexpression of SIRT1 inhibited the expression and activation of the main proinflammatory regulator NF-kB, which was increased by TNF-a. When SIRT1 was overexpressed in chondrocytes, the anti-inflammatory action of SIRT1 was similar to that exerted by resveratrol. Conclusions: SIRT1 activation deacetylates and inactivates NF-kB, and thereby, exerts an antiinflammatory effect on chondrocytes, suggesting that SIRT1 activators could be explored as potential treatments for arthritis.
Introduction
Osteoarthritis (OA) is the common joint disorder and is a leading cause of disability among the elderly. The disease is characterized by excessive production of several inflammatory mediators has been observed in OA 1 . Among these mediators, the proinflammatory cytokines interleukin (IL)-1b and tumor necrosis factor a (TNF-a), which are synthesized locally by synovial cells and chondrocytes, have been shown to play a central role in sustaining cartilage damage in arthritis by creating an imbalance between degradation and repair processes of cartilage 2, 3 . Moreover, TNFa has been shown to enhance degradation of the extracellular matrix (ECM) via activation of matrix metalloproteinases (MMPs). Degradation of the ECM in articular cartilage is the central event that leads to joint destruction in many arthritic conditions, including OA 4 . This proinflammatory effect is mediated by the induction of cyclooxygenase-2 (COX-2), which produces the inflammatory mediator prostaglandin E 2 (PGE 2 ) 5, 6 .
The expression and biological activity of the aforementioned proinflammatory factors are regulated by NF-kB. NF-kB regulates the expression of many genes involved in immune responses and inflammation 7 . When such cells are stimulated by cytokines, including IL-1b and TNF-a, which play important roles in the initiation and development of OA via activation of NF-kB pathways 5, 8 .
Recent reports showed that SIRT1 is a NAD þ -dependent deacetylase of numerous substrates. SIRT1 has been shown to mediate a variety of physiological events, including cell survival, increased metabolic rate, and higher oxygen consumption by deacetylation of target substrates 9, 10 . For example, SIRT1 deacetylates the p53 protein at lysine 382 and represses its transcriptional function to protect cells from apoptosis 11, 12 . Also, it was recently shown that SIRT1 proteins levels are reduced in chondrocytes derived from OA cartilage, compared to those derived from normal cartilage 13 . It has also been reported that SIRT1 inhibits apoptosis in various cell lines including chondrocytes 14 . Additionally, resveratrol, a natural product known to activate a number of cellular proteins, including SIRT1, was shown to enhance chondrocyte survival 15, 16 . Taken together, these studies suggest that SIRT1 may regulate chondrocyte survival in OA cartilage 15 . Thus, SIRT1 may conceivably be a key regulator of inflammation in mammalian cells via interaction with proinflammatory. In fact, SIRT1 was previously reported to play important inhibitory roles in sustained inflammation and in the aging of lungs 17 . The reported general antiinflammatory function of SIRT1 in model organisms suggests that SIRT1 may prevent the release of proinflammatory mediators and protect against ECM degradation in OA. However, to date, there have been no reports on the roles of SIRT1 in COX-2, PGE 2 and MMP production as well as activation of human chondrocytes. In this study, we explored the potential anti-inflammatory role of SIRT1 in human chondrocytes. Our findings indicate that SIRT1 is a potent anti-inflammatory protein and inhibits the COX-2/ MMP pathway via suppression of the potent proinflammatory factor NF-kB.
Materials and methods

Reagents
Resveratrol, purchased from Sigma (SigmaeAldrich, St. Louis, MO, USA), was prepared as a 100 mM solution in ethanol. Recombinant human TNF-a was purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Sirtinol, an SIRT1 inhibitor, was purchased from Sigma.
Chondrocyte isolation and monolayer cultures
Cartilage tissue samples were obtained from the tibial plateaus of knees from OA patients during joint replacement surgery, after receiving full informed consent from patients and local ethics committee approval. Full-thickness cartilage slices were obtained from a relatively lesion-free area above the subchondral bone. Human OA chondrocytes were harvested from the discarded knees as described previously 18 . Briefly, cartilage slices were chopped and incubated with 0.25% trypsin for 30 min, followed by 0.1% collagenase (SigmaeAldrich, St. Louis, MO, USA; #C6885) treatment for 6 h in DMEM (Invitrogen-Gibco, Grand Island, NY, USA) with 10% (v/ v) fetal bovine serum (FBS) (Invitrogen-Gibco) and antibiotics (100 mg mL À1 penicillinestreptomycin). Thereafter, cells were seeded in culture flasks in DMEM supplemented with 10% FBS and antibiotics. These first passage chondrocytes were used in subsequent experiments. Chondrocytes were incubated with DMEM containing 1% FBS prior to treatment with 0.5 % ethanol (vehicle control), resveratrol (12.5 to 200 mM), sirtinol (10 mM) and proinflammatory cytokines.
Construction of recombinant adenoviruses
SIRT1-expressing recombinant adenovirus (Ad-SIRT1) was used for SIRT1 experiments. LacZ-bearing adenovirus (Ad-LacZ) was used as a control. Recombinant adenoviruses were amplified in HEK-293 cells and purified using the Vivapure AdenoPACK kit (Sartorius AG, Goettingen, Germany) according to the manufacturer's instructions.
SIRT1 RNA interference
Human chondrocytes were transfected with validated Stealth TM siRNAs (Invitrogen, Carlsbad, CA, USA) directed against SIRT1 (oligo ID VHS50608; Invitrogen) using the Lipofectamine 2000 (Invitrogen). Nonspecific siRNA (oligo ID 12935e300; Invitrogen) was used as a negative control 12 .
RT-PCR
Total RNA was extracted from human chondrocytes using the Easy-spinÔ total RNA extraction kit (iNtRON Biotechnology, Seoul, Korea). The mRNA expressions of COX-2 and MMPs were analyzed by RT-PCR using specific primer sets. The sequences of the primers used for the RT-PCR were as follows:
COX-2: forward, 5 0 AGTCCCTGAGCATCTACGGTTTG3 0 , reverse, 5 0 CATCGCATACTCTGTTGTGTTCCC3 0 ; MMP-1: forward, 5 0 TCCACTGCTGCTGCTGCTG3 0 , reverse, 5 0 TTTC AACTTGCCTCCCATCATTCTTC3 0 ; MMP-3: forward, 5 0 TGAACAATGGACAAAGGATACAACAGG3 0 , reverse, 5 0 ATCATCTTGAGACAGGCGGAACC3 0 ; MMP-13: forward, 5 0 AGTGGTGGTGATGAAGATGATTTGTC3 0 , reverse, 5 0 TCTAAGGTGTTATCGTCAAGTTTGCC3 0 ; b-actin: forward, 5 0 GCAAGCAGGAGTATGACGAG3 0 , reverse, 5 0 CA AATAAAGCCATGCCAATC3 0 .
The sizes of the products were checked by agarose gel electrophoresis. Images thereof were captured using the Fusion FX7 system (Vilber Lourmat, Eberhardzell, Germany).
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted from chondrocytes using the Easy-spinÔ total RNA extraction kit (iNtRON Biotechnology, Seoul, Korea). qRT-PCR was performed using 1 ml of SYBR Green Master mix (Bio-Rad Laboratories, Hercules, CA, USA) primers to a total reaction volume of 20 ml. The sequences of the primers used for the qRT-PCR were as follows:
COX-2: forward, 5 0 AGTCCCTGAGCATCTACGGTTTG3 0 , reverse, 5 0 CATCGCATACTCTGTTGTGTTCCC3 0 ; MMP-1: forward, 5 0 TCCACTGCTGCTGCTGCTG3 0 , reverse, 5 0 TTTC AACTTGCCTCCCATCATTCTTC3 0 ; b-actin (as an internal control): forward, 5'GCAAGCAGGAGTATG ACGAG3', reverse, 5 0 CAAATAAAGCCATGCCAATC3 0 .
All reactions were performed with iTaq SYBR Green Supermix (Bio-Rad Laboratories) using the CFX96 real-time PCR detection system (Bio-Rad Laboratories).
Western blot
Chondrocytes were lysed in buffer (25 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 5 mM MgCl 2 , 0.1 mM DTT, and a protease inhibitor mixture). Equal amounts of lysate protein were electrophoretically resolved by 10e 15% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (SDS-PAGE). Images thereof were captured using the Fusion FX7 system (Vilber Lourmat, Eberhardzell, Germany). The densitometry of the signal bands was analyzed using Bio-1D software (Vilber Lourmat, Marne La Vallee, France). Antibodies against COX-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p-65 (Millipore), acetyl p-65 (Cell Signaling Technology, Beverly, MA, USA), SIRT1 (Santa Cruz Biotechnology) and ß-actin (SigmaeAldrich, St. Louis, MO, USA) were used to perform the immunoblotting experiments.
Immunofluorescent staining
Cells were cultured on glass slides, fixed with cold acetone, blocked by 5% FBS in TBST. They were incubated with mouse NF-kB (active p-65 subunit) antibody (Millipore), goat COX-2 antibody (Santa Cruz Biotechnology), and rabbit SIRT1 antibody (Santa Cruz Biotechnology) at 4 C. Cells were incubated with anti-mouse IgG conjugated with Alexa Fluor Ò 488, anti-goat IgG conjugated with Alexa Fluor Ò 350 and anti-rabbit IgG conjugated with Alexa Fluor Ò 546. Thereafter, cells were observed under a fluorescence microscope (Nikon ECLIPSE 80i, Nikon Corporation).
Quantification of glycosaminoglycan (GAG) release
Cartilage explants were treated with TNF-a with or without resveratrol for 72 h. GAG levels in the culture media were then determined by reacting samples with 1,9-dimethylmethylene blue.
Thereafter, 20 ml of sample media or chondroitin sulfate were mixed with 180 ml of DMB reagents (48 mg/ml DMB, 40 mM glycine, 40 mM NaCl, 10 mM HCl, pH 3.0) at room temperature. Absorbance at 525 nm was then measured with a spectrophotometer (Spectramax, Molecular Devices, Sunnyvale, CA, USA). All measurements were performed in quadruplicate. Quantification was performed using a standard curve of chondroitin sulfate. Results were normalized to protein concentrations of GAG release.
Analysis of PGE 2 levels via enzyme-linked immunosorbent assay (ELISA)
Chondrocytes were incubated with DMEM containing 1% FBS prior to treatment with or without TNF-a (10 ng/ml), resveratrol and sirtinol for 24 h. PGE 2 levels in the culture media were quantified using an immunoenzymatic method (PGE 2 EIA kits, Cayman Chemicals, Ann Arbor, MI, USA) according to the manufacturer's specifications.
Gelatin zymography
The supernatant was resolved on SDS-PAGE gels containing 10% acrylamide and 1 mg/ml gelatin. The gels were then washed with 2.5% (w/v) Triton X-100 at room temperature and incubated overnight in a developing buffer containing 50 mM TriseHCl (pH 7.5), 0.2 M NaCl and 5 mM CaCl 2 . Gels were stained with 0.2% Coomassie Blue R-250 in 50% ethanol and 10% acetic acid at room temperature and destained with a buffer comprising 20% methanol, 10% acetic acid at room temperature. The gels were analyzed using the Fusion FX7 system (Vilber Lourmat, Eberhardzell, Germany).
Statistical evaluation
All data were expressed as mean AE standard deviation (SD) and analyzed by one-way analysis of variance (ANOVA) with Tukey's post test for multiple groups using GraphPad Prism Version 5.0. Means sharing a common alphabetical symbol indicate not significantly different values.
Results
Resveratrol, an SIRT1 activator, inhibits TNF-a-induced inflammatory factor release and ECM degradation
The proinflammatory cytokine TNF-a contributes to the pathogenesis of OA and is a potent enhancer of COX-2, which plays a pivotal role in the cartilage inflammation 5,19e22 . Consistent with, cells exposed to TNF-a resulted in increase in COX-2 mRNA expression [ Fig. 1 As up-regulation and activation of MMP expression has been associated with a loss of cartilage matrix 23 , we investigated the effect of resveratrol on MMP production and activation. A previous study found that MMP-1, MMP-3 and MMP-13 were detectable in OA synovial fluids and were produced in vitro by both the synovium and chondrocytes in response to inflammatory cytokines 2 . Consistent with the results from that study, we found that TNFa treatment induced significant up-regulation of MMP-1, MMP-3 and MMP-13 mRNA expression. Additionally, resveratrol treatment dose-dependently decreased the observed TNF-a-induced increase in MMP mRNA expression [ Fig. 1(C) ]. Moreover, through gelatin zymography, we indentified that resveratrol prevented the TNF-ainduced activation of MMP-2 and MMP-9 [ Fig. 1(D) ]. Accordingly, these results indicated that resveratrol exerts anti-inflammatory effects by decreasing the expression of COX-2 and MMPs.
To further evaluate the chondroprotective effect of resveratrol treatment, we investigated whether resveratrol would prevent TNF-a-induced degradation of cartilage matrix. When cartilage explants were treated with TNF-a, the amounts of GAG released from cartilage explants into the media were significantly increased. Meanwhile, the treatment of resveratrol successfully inhibited TNF-a-induced increase in GAG release from cartilage explants [ Fig. 1(E) ]. These results indicate that resveratrol was effective in preventing TNF-a-mediated release of GAG into the media of cartilage explant cultures.
SIRT1 protein up-regulation by resveratrol protects against TNF-a in human chondrocytes
Resveratrol increases the deacetylase activity of several sirtuin members, including the mammalian ortholog SIRT1, which is known to exhibit anti-inflammatory activity 17, 24 . To investigate whether resveratrol regulates SIRT1 protein expression and deacetylase activity, human chondrocytes were treated with resveratrol at concentrations of 12.5, 50 and 200 mM. Resveratrol increased SIRT1 protein expression in a dose-dependent manner and this was blocked by the SIRT1 inhibitor, sirtinol [ Fig. 2 (A) and (B)]. Remarkably, treatment with TNF-a resulted in a down-regulation in SIRT1 protein expression, which was reversed by treatment with resveratrol [ Fig. 2(B) ].
SIRT1 interacts with and regulates histones and various transcription factors, such as NF-kB p-65 and FOXO. Since activation of NF-kB is known to play a pivotal role in the development of OA and to lead to ECM damage and cartilage destruction 7 , it was hypothesized that this factor may be involved in the resveratrol-induced anti-inflammatory activity observed in human articular chondrocytes. Accordingly, we assessed whether resveratrol contributes to the deacetylation of p-65. As shown in Figs. 2(C) and 3(A), acetylation of p-65 was dose-dependently reduced in resveratrolpretreated cells and this reduction was blocked by the SIRT1 inhibitor sirtinol.
We further investigated whether activated SIRT1 regulates other proteins potentially associated with inflammation. Accordingly, resveratrol decreased the expression of the proinflammatory protein COX-2 [ Fig. 3(B) ]. The reduction in COX-2 protein expression by resveratrol was prevented by sirtinol [ Fig. 3(B) ]. This suggests that SIRT1 may be involved in the resveratrol-mediated inhibition of inflammatory cytokine production.
Knockdown of SIRT1 by siRNA suppresses resveratrolmediated anti-inflammatory activity
To confirm the relationship between SIRT1, NF-kB p-65 and COX-2 inactivation, we used siRNA to inhibit SIRT1 in human articular chondrocytes and determined the effects of SIRT1 knockdown on the resveratrol-mediated anti-inflammatory effect against TNF-a. Human articular chondrocytes were transfected with either SIRT1 siRNA and treated with TNF-a (50 ng/ml) and/or resveratrol (200 mM) for 24 h. Accordingly, SIRT1 protein expression level was markedly decreased in SIRT1 siRNA-treated cells relative to control siRNA-treated cells [ Fig. 4(C and D) ]. Moreover, SIRT1 mRNA level was markedly increased by treatment with resveratrol in control siRNA-treated cells, while knockdown of SIRT1 led to reduced levels of SIRT1 mRNA compared to those treated with control siRNA. However, there was no change in SIRT1 mRNA expression level after resveratrol stimulation in SIRT1 siRNAtreated cells [ Fig. 5(A) ]. In accordance with the above findings regarding the effect of sirtinol on COX-2 protein expression, resveratrol, an SIRT1 inhibitor, completely lost its ability to impair proinflammatory factor activation when SIRT1 was silenced ( Fig. 4 ). Furthermore, although TNF-a treatment significantly increased p-65 acetylation and activation [ Fig. 4(A) ], as well as COX-2 mRNA [ Fig. 5(B) ] and protein expression [ Fig. 4(B) and (D)], pretreatment with resveratrol impaired the activation of these proinflammatory factors. However, silencing of SIRT1 resulted in no change in TNF-ainduced p-65 activation and COX-2 up-regulation ( Fig. 4) .
Next, we evaluated whether resveratrol-induced down-regulation of the expression of major MMP mRNAs, which are involved in ECM degradation, is a SIRT1-mediated process. Knockdown of SIRT1 using siRNA restored MMP-1 and MMP-13 mRNA levels to those observed in TNF-a treated cell [ Fig. 5 (C) and (D)]. In addition, down-regulation of SIRT1 prevented the inhibitory effect of resveratrol on proinflammatory factor expression and activation, indicating that SIRT1 is responsible for the association between resveratrol and chondrocyte protection against TNF-a.
Adenoviral overexpression of SIRT1 results in antiinflammatory activity
To directly ascertain the anti-inflammatory role of SIRT1 in the TNF-a-induced proinflammatory response observed in human chondrocytes, cells were infected with adenoviruses expressing was analyzed 24 h after TNF-a treatment using gelatin zymography. The lower panels show blots that were stripped and re-probed with specific anti-b-actin antibodies. The bar graph indicates the mean AE SD (n ¼ 3). The data were analyzed using ANOVA and Tukey multiple range tests (P < 0.01). Means sharing a common alphabetical symbol did not significantly differ. (E), Human cartilage explants were treated for 72 h with the indicated concentrations of resveratrol and TNF-a (50 ng/ml). GAG released into the culture media was assessed using dimethylmethylene blue. The data are results from three different experiments. The data were analyzed using ANOVA and Tukey multiple range tests (P < 0.01). Means sharing a common alphabetical symbol did not significantly differ. TNF-a is known to stimulate the production of MMPs, enzymes that have been shown to degrade all components of the ECM. Not surprisingly, MMP production and activation have been shown to play an important role in OA progression 25, 26 . To determine whether the chondroprotective effects of SIRT1 might be associated with a disturbance in MMP expression, MMP mRNA expression was analyzed in human chondrocytes infected with Ad-SIRT1 or Ad-LacZ and exposed to TNF-a (50 ng/ml) for 12 h. Quantitative RT-PCR experiments revealed that overexpression of SIRT1 significantly reduced the mRNA expressions of MMP-1, MMP-3 and MMP-13 in human chondrocytes treated with TNF-a ( Fig. 7) . Together, these results provide further evidence that the antiinflammatory effects of resveratrol are due to the downregulation of NF-kB p-65/COX-2/MMPs pathways via activation of SIRT1, suggesting that SIRT1 may play a pivotal role in chondroprotection against proinflammatory cytokines. 5. SIRT1 regulates PGE 2 production in TNF-a-mediated inflammation PGE 2 , which originates from activation of the COX pathways, is produced by OA chondrocytes and can promote matrix degeneration 15, 27 . Accordingly, we further evaluated the chondroprotective effect of SIRT1 by assessing PGE 2 production in culture media [ Fig. 8(A) and (B) ]. The production of PGE 2 was increased by stimulation of TNF-a in the supernatants of conditioned media [ Fig. 8(A) and (B)]. After treatment with resveratrol, PGE 2 synthesis was significantly reduced to the level of the control group [ Fig. 8(A) ].
Next, we investigated whether the action of resveratrol is mediated by SIRT1. Selective knockdown of SIRT1 using siRNA abolished the observed resveratrol-stimulated reduction in TNF-amediated PGE 2 production [ Fig. 8(A) ]. To further study the direct relationship between SIRT1 and PGE 2 production, we used an adenovirus vector system to overexpress SIRT1 proteins. Overexpression of SIRT1 significantly rescued the up-regulation of PGE 2 production caused by TNF-a [ Fig. 8(B) ] (treatment with 0.9 ng/ml TNF-a vs infection with 0.5 ng/ml Ad-SIRT1 before TNF-a treatment; P < 0.05). As expected, LacZ vector infection in human chondrocytes demonstrated no effect on PGE 2 production. These results suggest that resveratrol prevents inflammatory cytokineinduced PGE 2 synthesis via activation of SIRT1.
Discussion
Sirtuin 1 (SIRT1) is known to deacetylate histones and nonhistone proteins, including transcription factors, thereby regulating metabolism and inflammation-immune function 28 . SIRT1 was previously shown to act as a novel immunomodulator in chronic inflammatory diseases, such as diabetes and colitis by modulating the NF-kB-dependent pathway 28 . Furthermore, it also inhibited the expression of various genes that encode other proinflammatory factors, such as COX-2 and MMPs via downregulation of NF-kB 15,28e30 . However, the role of SIRT1 in OA pathogenesis has primarily been studied with respect to chondrocyte apoptosis 14, 15, 31 , while the anti-inflammatory effect of SIRT1 in chondrocytes remains largely unknown.
In this study, we investigated the effects of SIRT1 on chondrocyte metabolism, particularly on the catabolic effects induced by the OA-associated TNF-a. We found that SIRT1 acts as a negative regulator of inflammation and that SIRT1 activity is mediated by the NF-kB/COX-2/MMPs pathway. Furthermore, we have also demonstrated that treatment with the resveratrol effectively inhibited the activation of proinflammatory factors by activating SIRT1, leading to deacetylation of NF-kB p-65 and subsequent down-regulation of TNF-a-induced COX-2 and MMP expression in articular chondrocytes.
Resveratrol was the first polyphenolic compound shown to activate SIRT1, and is well known to exhibit anti-inflammatory activity 32, 33 . Furthermore, we have also demonstrated that treatment with the resveratrol effectively inhibited the activation of proinflammatory factors by activating SIRT1, leading to deacetylation of NF-kB p-65 and subsequent down-regulation of TNF-ainduced COX-2 and MMP expression in articular chondrocytes.
Proinflammatory cytokines such as TNF-a and IL-1b have been shown to mediate cartilage degradation in OA in humans as well as in animals 2 . Previously, TNF-a was found to stimulate transcription of a smaller inactive SIRT1 protein product (an enzymatically inactive Sirt1 fragment the size of 75 kD) by cleavage of normal SIRT1 34 . Consistent with this finding, we observed that SIRT1 mRNA levels were increased by TNF-a treatment [ Fig. 5(A) ].
Also, TNF-a is known to activate ubiquitous NF-kB, leading to further production and up-regulation of proinflammatory cytokines and enzymes such as COX-2 and MMPs, which in turn produce prostaglandins (PGs) and degrade ECM macromolecules, promoting cartilage degradation and further joint inflammation 35 . MMP-1 is expressed in various cell types, including chondrocytes and fibroblasts, and is most effective in degrading type III collagen. MMP-13 is expressed mainly by articular chondrocytes, and preferentially cleaves type II collagen as well as aggrecan, a proteoglycan important for the resiliency of normal articular cartilage 25, 26, 36, 37 . The collagenases, MMP-1 and MMP-13, play predominant roles in RA and OA because they are rate-limiting factors in the process of collagen degradation 25, 26, 36 . Thus, they are postulated to also play an important role in the destruction of cartilage.
Since MMP induction is considered a key mediator of cartilage destruction, we assessed the influence of SIRT1 on MMP production. As expected, activation of SIRT1 by resveratrol treatment reduced MMP-1 and MMP-13 production, as well as MMP-2 and MMP-9 activation, which were significantly blocked by SIRT1 siRNA (Fig. 5 ). Moreover, overexpression of SIRT1 significantly decreased TNF-a-induced production and activation of MMP (Fig. 7) . In addition to collagen, MMP-13 also degrades the proteoglycan molecule, aggrecan, giving it a dual role in matrix destruction. The expression of other MMPs, such as MMP-2, MMP-3 and MMP-9, has also been shown to be elevated in arthritis, as these enzymes degrade the non-collagen matrix components of joints 25, 26, 36 . In this study, resveratrol treatment was shown to reduce MMP-13 mRNA expression level, and provide protection against proteoglycan destruction [ Fig. 1(E) ]. Accordingly, these results suggest that SIRT1 inhibits the ECM degradation caused by proinflammatory cytokines by reducing MMP production and activation.
NF-kB activation plays a major role in OA progression. The nuclear function of the heterodimeric NF-kB transcription factor is regulated in part by the reversible acetylation of its RelA subunit. Acetylation of lysine 310 is required for full transcriptional activity of RelA 38e40 . This process is reciprocally regulated by histone deacetylases (HDACs), in fact, several HDAC inhibitors have been shown to activate NF-kB. In the present study, we demonstrated that TNF-a enhances the activation of NF-kB p-65, and that resveratrol decreased the acetylation of NF-kB p-65. Interestingly, whereas blockade of SIRT1 using sirtinol or siRNA significantly inhibited the resveratrol-induced deacetylation of NF-kB p-65 ( Figs. 4 and 5) , overexpression of SIRT1 induced the inactivation and deacetylation of NF-kB p-65 ( Figs. 6 and 7) . These results suggest that the anti-inflammatory activity of SIRT1 (i.e., downregulation of MMPs and COX-2) stems from the inhibition of NF-kB activation, given the crucial role of NF-kB p-65 in MMP production. COX-2, one of the classic NF-kB targets, is known as the ratinglimiting enzyme in PG production. In addition, as observed in this study, the protective effects of SIRT1 on ECM metabolism were consistent with its capacity to inhibit TNF-a-mediated production of PGE 2 . Previous studies have shown that the addition of PGE 2 upregulates MMP-1 synthesis both in chondrocytes and in synovial fibroblasts 15 . Our results showed that while overexpression of SIRT1 dramatically decreased PGE 2 production, silencing of SIRT1 significantly abolished the activity of SIRT1, increasing PGE 2 level to that of the control group (Fig. 8 ). PGE 2 synthesis was, accordingly, discerned to be regulated by SIRT1, and increased PGE 2 level resulted in MMP production. Furthermore, while knockdown of SIRT1 abolished the ability of SIRT1 to inhibit MMP-1 and MMP-13 mRNA expression ( Fig. 5 ), overexpression of SIRT1 reduced MMP expression in an M.O.I.-dependent manner (Fig. 7) .
In conclusion, the results of this study show that SIRT1 inhibits inflammatory responses in human articular chondrocytes, as confirmed by a reduction in GAG release and a reduction in the treated with or without TNF-a (10 ng/ml) for 24 h. Culture supernatants were collected and PGE 2 production was determined by ELISA. The bar graph indicates the mean AE SD (n ¼ 3). The data were analyzed using ANOVA and Tukey multiple range test (P < 0.01). Means sharing a common alphabetical symbol did not significantly differ. expressions of COX-2, PGE 2 and MMPs, using siRNA and adenoviral vector transfection techniques. Accordingly, SIRT1 was discerned to function as an anti-inflammatory compound in human chondrocytes. In addition, NF-kB p-65 was shown to be responsible for the anti-inflammatory activity of SIRT1. These results suggest that SIRT1 activation might be a potential therapeutic target in OA. Therefore, development of SIRT1-specific activators including resveratrol may show promise as potential medical interventions.
